BioCryst Pharmaceuticals,Inc. (BCRX)

[apollo1452]

Congrats BCRX Longs !!!
Remember the gap BCRX has at $7.20 from 5/20/19. Now that Berotralstat/Orladeyo is APPROVED that gap WILL be filled. Maybe not tomorrow but with the multiple catalysts & revenue on deck it will happen in the near future.

With Institutions holding about 90% of the float they can do as they please with the share price given the right catalyst & demand exceeding supply, plus fuel from the large short interest covering.

**CATALYSTS Q4 & Q1**
*Bero/Orladeyo FDA Approved!
*Orladeyo granted Early Access by UK's MHRA
*Bero/Orladeyo Japanese approval - Waiting on official decision from Japanese Ministry of Health in Dec 2020.
Japanese ADCOM already recommended approval.
*Galidesivir antiviral COVID-19 Brazilian clinical trial, Part 1 data Dec 2020
*BCX9250 Fibrodysplasia Ossificans Progressiva (FOP)P1 data Q4
*BCX9930 Factor D 200/400mg Cohort 2 data Q1
*Bero/Orladeyo EU approval decision 2021
*RAPIVAB possible flu stockpile orders.